Aimmune Therapeutics Inc

Overview

Aimmune Therapeutics Inc (Aimmune) formerly Allergen Research Corp is a clinical-stage biopharmaceutical company. It develops proprietary product candidates for the treatment of peanut and other food allergies. Aimmune's product pipeline includes AR101- Peanut Allergy Powder-dnfp (PALFORZIA), used to treat the peanut allergy. Its pipeline program portfolio uses characterized oral desensitization immunotherapy (CODIT), a proprietary approach to oral immunotherapy. In addition, Aimmune also discovers, develops and commercializes therapies related to food allergy. The company conducts academic research in partnership with various universities and other companies to develop novel product candidates. The company operates in the US and the UK. Aimmune is headquartered in Brisbane, California, the US.
Key Stats
Address
Suite 300, 8000 Marina Blvd., Brisbane, California
Headquarters

United States of America

Contact

1 650 6145220

Website
www.aimmune.com
No of Employees

261

Industry

Pharmaceuticals and Healthcare

Peer Comparison

Key Parameters Aimmune Therapeutics IncExelixis IncSoligenix IncImmune Design Corp (Inactive)
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City Brisbane ALAMEDA PRINCETON Seattle
Headquarter State/Province California California New Jersey Washington
No. of Employees 261 773 17 48
Entity Type Private Public Public Private

Products & Services

Aimmune is a provider of clinical-stage biopharmaceutical products. Key products offered by the company include the following:

Products
  • Pipeline
  • AR101- Peanut Allergy Powder-dnfp (PALFORZIA)

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Financing Agreements In February, the company announced to secure US$200 million funding from Nestle Health Science.
2020 Contracts/Agreements In August, the company entered into an agreement to be acquired by Nestle Health Science…
2018 Ownership Changes In November, Nestle Health Science increased its equity stake in the company to 19% stake.
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Aimmune Therapeutics UK Limited
Aimmune Therapeutics (Bermuda), Ltd.
Aimmune Therapeutics Netherlands B.V.

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
31 Aug 2020 Societe Des Produits Nestle Acquires Aimmune Therapeutics Acquisition Societe Des Produits Nestle SA Aimmune Therapeutics Inc
05 Feb 2020 Aimmune Therapeutics to Raise USD200 Million in Private Placement Equity Offering Nestle Health Science Aimmune Therapeutics Inc
05 Feb 2020 Aimmune Therapeutics Enters into Licensing Agreement with Xencor Licensing Agreement Aimmune Therapeutics Inc Xencor Inc
14 Nov 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
14 Nov 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
01 May 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

19

Active Jobs

12

Posted

11

Closed

Job Trends

Latest Jobs

Job title Company Country
Director, Global Health Economics and Payer Evidence Aimmune Therapeutics Inc United States
Director Regulatory Operations and Information Systems Aimmune Therapeutics Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar